Literature DB >> 28019637

Recent Advances in Targeted Therapy for Glioma.

Lin Lin1,2,3,4, Jinquan Cai1,2,3,4, Chuanlu Jiang1,2,3,4.   

Abstract

Gliomas are the most common primary malignant brain tumors, which have a universally fatal outcome. Current standard treatment for glioma patients is surgical removal followed by radiotherapy and adjuvant chemotherapy. Due to therapeutic resistance and tumor recurrence, efforts are ongoing to identify the molecules that are fundamental to regulate the tumor progression and provide additional methods for individual treatment of glioma patients. By studying the initiation and maintenance of glioma, studies focused on the targets of tyrosine kinase receptors including EGFR, PDGFR and other crucial signal pathways such as PI3K/AKT and RAS/RAF/MAPK pathway. Furthermore, recent advances in targeting immunotherapy and stem cell therapy also brought numerous strategies to glioma treatment. This article reviewed the researches focused on the advanced strategies of various target therapies for improving the glioma treatment efficacy, and discussed the challenges and future directions for glioma therapy. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Glioma; Immunotherapy; cell signal transduction pathway; clinical trials; glioma stem cell; targeted therapy

Mesh:

Substances:

Year:  2017        PMID: 28019637     DOI: 10.2174/0929867323666161223150242

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  35 in total

1.  IFITM3/STAT3 axis promotes glioma cells invasion and is modulated by TGF-β.

Authors:  Hongliang Wang; Feng Tang; Erbao Bian; Yile Zhang; Xinghu Ji; Zhihao Yang; Bing Zhao
Journal:  Mol Biol Rep       Date:  2019-10-21       Impact factor: 2.316

2.  MicroRNA-6852 suppresses glioma A172 cell proliferation and invasion by targeting LEF1.

Authors:  Jialiang Wang; Haipeng Liu; Kebin Zheng; Shuai Zhang; Wei Dong
Journal:  Exp Ther Med       Date:  2019-07-09       Impact factor: 2.447

3.  LncRNA H19 Promotes Cell Proliferation, Migration, and Angiogenesis of Glioma by Regulating Wnt5a/β-Catenin Pathway via Targeting miR-342.

Authors:  Qin Zhou; Zheng-Zheng Liu; Heng Wu; Wei-Lu Kuang
Journal:  Cell Mol Neurobiol       Date:  2020-11-07       Impact factor: 5.046

4.  miRNA-451 regulates the NF-κB signaling pathway by targeting IKKβ to inhibit glioma cell growth.

Authors:  Yang Nan; Liyun Guo; Yingwei Zhen; Le Wang; Bingcheng Ren; Xingjie Chen; Yalin Lu; Kai Yu; Yue Zhong; Qiang Huang
Journal:  Cell Cycle       Date:  2021-08-31       Impact factor: 5.173

5.  Inhibition of DNA-PK potentiates the synergistic effect of NK314 and etoposide combination on human glioblastoma cells.

Authors:  Paulina Kopa; Anna Macieja; Izabela Gulbas; Elzbieta Pastwa; Tomasz Poplawski
Journal:  Mol Biol Rep       Date:  2019-10-03       Impact factor: 2.316

6.  Loss of GINS2 inhibits cell proliferation and tumorigenesis in human gliomas.

Authors:  Yun-Long Shen; He-Zhen Li; Yan-Wei Hu; Lei Zheng; Qian Wang
Journal:  CNS Neurosci Ther       Date:  2018-10-18       Impact factor: 5.243

7.  Downregulation of circ_0037655 impedes glioma formation and metastasis via the regulation of miR-1229-3p/ITGB8 axis.

Authors:  Wenhui Zou; Yalei Cao; Kai Cheng; Changyu Li; Fu Zhu; Shumao Yang; Maolin Jin; Shaojun Song
Journal:  Open Life Sci       Date:  2021-05-10       Impact factor: 0.938

8.  circ_0030018 promotes glioma proliferation and metastasis.

Authors:  Yun Shao; Zhengxiang Yang; Weifeng Miao; Xiangrong Yu; Yiping Wu; Yi Pu
Journal:  Transl Neurosci       Date:  2021-06-09       Impact factor: 1.757

Review 9.  The Roles Played by Long Non-Coding RNAs in Glioma Resistance.

Authors:  Yeonsoo Chae; Jungwook Roh; Wanyeon Kim
Journal:  Int J Mol Sci       Date:  2021-06-25       Impact factor: 5.923

10.  Multi-responsive nanofibers composite gel for local drug delivery to inhibit recurrence of glioma after operation.

Authors:  Yufu Zhu; Jun Jia; Gang Zhao; Xuyang Huang; Lansheng Wang; Yongkang Zhang; Long Zhang; Naveena Konduru; Jun Xie; Rutong Yu; Hongmei Liu
Journal:  J Nanobiotechnology       Date:  2021-07-03       Impact factor: 10.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.